AA
CLVS

Antipodean Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Antipodean Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-523,000
Closed -$7.18M – 20
2016
Q2 		$7.18M Sell
523,000
-536,901
-51% -$7.85M 4.34% 9
2016
Q1 		$20.4M Sell
1,059,901
-208,757
-16% -$4.42M 9.23% 3
2015
Q4 		$44.4M Sell
1,268,658
-37,833
-3% -$2.44M 6.48% 9
2015
Q3 		$120M Buy
+1,306,491
New +$113M 13.68% 2

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Antipodean Advisors's CLVS Position: Q3 2016 in Review

Antipodean Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2016, closing a stake of 523,000 shares — an estimated $7.18M sold.

Antipodean Advisors first reported a position in CLVS in Q3 2015 and held it in 4 quarters. The position peaked at $120M in Q3 2015. 163 funds tracked by Wall St. Rank hold CLVS as of Q3 2016.

  • Antipodean Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2016 after selling out during the quarter.
  • Antipodean Advisors sold 523,000 Clovis Oncology, Inc. shares in Q3 2016, an estimated $7.18M.
  • Antipodean Advisors first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 4 quarters.
  • Antipodean Advisors's Clovis Oncology, Inc. position peaked at $120M in Q3 2015.
  • 163 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2016.

Based on Antipodean Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.